Investor News

Acorda Named One of the 100 Best Workplaces for Women by Fortune and Great Place to Work

ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the 100
Best Workplaces for Women based on an independent survey by Fortune
and Great Place to Work®. The survey included more than
135,600 female employees at companies of all sizes based in the United
States. This recognition is based on women’s assessments of the quality
and fairness of their workplace.

“Acorda is focused on developing medicines that can change people’s
lives. To do so successfully requires close collaboration among people
with a wide diversity of perspectives and experiences, and rewards based
solely on performance. Our culture emphasizes these values, while also
fostering work/home life balance,” said Denise Duca, Executive Vice
President, Human Resources of Acorda. “We are proud that the talented
women who work at Acorda view this as a great place to build a career
and to make valuable contributions to advancing healthcare.”

In addition to being named as one of the Best Workplaces for Women in
2015, Acorda has been recognized as one of the Best Places to Work in
New York for the past five years in a row by the Best Companies Group,
ranking 3rd in 2015 among large employers (250+ associates).

Factors such as the fairness of promotions, access to information and
leadership, level of support for employees’ personal lives, and degree
of inclusiveness and connection with colleagues were inclusion criteria
for the Best Workplaces for Women list. Scores also take into account
how well-represented women are within the workforce, management and
executive positions; how positively women experience their workplace’s
fairness; and how favorable women’s experiences are compared to the
138,000 men also surveyed.

The analysis showed that the companies recognized as Best Workplaces for
Women create a more consistent and inclusive environment across a range
of day-to-day trust-building behaviors, including employees’ access to
special recognition, fair treatment regardless of role, and management
approachability.

About Acorda Therapeutics

Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with
neurological disorders.

Acorda markets three FDA-approved therapies, including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg. The Company has one of
the leading pipelines in the industry of novel neurological therapies.
Acorda is currently developing a number of clinical and preclinical
stage therapies. This pipeline addresses a range of disorders including
post-stroke walking deficits, Parkinson’s disease, epilepsy, heart
failure, MS and spinal cord injury.

For more information, please visit the Company’s website at: www.acorda.com.

Forward Looking Statements

This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including the ability to realize the benefits anticipated from the
Civitas transaction and to successfully integrate Civitas' operations
into our operations; our ability to successfully market and sell Ampyra
in the U.S.; third party payers (including governmental agencies) may
not reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz (diazepam) Nasal Spray,
or any other acquired or in-licensed programs; we may not be able to
complete development of, obtain regulatory approval for, or successfully
market CVT-301, Plumiaz, or any other products under development; we may
need to raise additional funds to finance our expanded operations and
may not be able to do so on acceptable terms; the occurrence of adverse
safety events with our products; delays in obtaining or failure to
obtain regulatory approval of or to successfully market Fampyra outside
of the U.S. and our dependence on our collaboration partner Biogen in
connection therewith; competition; failure to protect our intellectual
property, to defend against the intellectual property claims of others
or to obtain third party intellectual property licenses needed for the
commercialization of our products; and, failure to comply with
regulatory requirements could result in adverse action by regulatory
agencies.

These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in this
release are made only as of the date hereof, and Acorda disclaims any
intent or obligation to update any forward-looking statements as a
result of developments occurring after the date of this release.